NCT01550926View on ClinicalTrials.gov

A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Overweight
Interventions
DRUG

120 mg orlistat

2 X60 mg capsule

DRUG

60 mg orlistat

60 mg orlistat

DRUG

orlistat experimental dose

experimental

Trial Locations (1)

BT9 6AD

MDS Pharma Services, Belfast

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY